Cancers & treatments·Regimen libraryFirst line

GEMOX

Checked 2026-09-09

Advanced biliary tract cancer when cisplatin is unsuitable; also used in pancreatic cancer and some lymphomas

Also called GEMCITABINE-OXALIPLATIN, gemcitabine-oxaliplatin.

One cycle

every 14 days

14-day cycle, until progression or 6 monthsIntravenous

Components

Drug	Dose	Route	Days	Note
Gemcitabine Nucleoside analogue (deoxycytidine)	1,000 mg/m²	IV	D1
Oxaliplatin Third-generation platinum (DACH-platinum)	100 mg/m²	IV	D2

Cycles

until progression or 6 months

14-day cycle

Emetogenicity

Moderate (30-90%)

G-CSF

Not routine

Notes

Gemcitabine plus cisplatin (with durvalumab or pembrolizumab) is the reference first-line regimen in biliary cancer; GEMOX is the cisplatin-free alternative.
Cumulative oxaliplatin neuropathy limits duration.

Used in

Biliary tract cancer (cholangiocarcinoma)Gallbladder cancer Pancreatic ductal adenocarcinoma

Products

GemcitabineOxaliplatin

Source

André, Annals of Oncology 2004: GEMOX in advanced biliary tract adenocarcinoma

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.